Unknown NA INTERVENTIONAL 1-arm NCT06061445

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

A Study to Evaluate the Effects of Radiotherapy Combined With Tyrosine Kinase Inhibitor (TKI) and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(PVTT)

Sponsor: Fujian Cancer Hospital

Conditions Stage IIIA Hepatocellular Carcinoma

Interventions Radiotherapy combined with TKI and Anti-PD-1 Antibody

Updated 5 times since 2023 Last updated: Apr 10, 2024 Started: Jan 9, 2024 Primary completion: Jul 30, 2024 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06061445, this NA trial focuses on Stage IIIA Hepatocellular Carcinoma and remains ongoing. Sponsored by Fujian Cancer Hospital, it has been updated 5 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Unknown NA

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
May 2024 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting · Phase: PHASE2 → NA
Oct 2023 — May 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Cancer Hospital

Data source: Fujian Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fuzhou, China